Valproic acid induced liver injury: An insight into molecular toxicological mechanism.

[1]  Weifeng Huang,et al.  Mitochondrial stress response in drug-induced liver injury , 2021, Molecular Biology Reports.

[2]  S. Bolkent,et al.  Vitamin U prevents valproic acid-induced liver injury through supporting enzymatic antioxidant system and increasing hepatocyte proliferation triggered by inflammation and apoptosis , 2021, Toxicology mechanisms and methods.

[3]  H. Jaeschke,et al.  Mitochondrial Dynamics in Drug-Induced Liver Injury , 2021, Livers.

[4]  K. Ouguerram,et al.  Epigenetic Regulation of Peroxisome Proliferator-Activated Receptor Gamma Mediates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease , 2021, Cells.

[5]  H. Kalantari,et al.  Taurine attenuates valproic acid-induced hepatotoxicity via modulation of RIPK1/RIPK3/MLKL-mediated necroptosis signaling in mice , 2021, Molecular Biology Reports.

[6]  D. Ezhilarasan.  Mitochondria: A critical hub for hepatic stellate cells activation during chronic liver diseases: Mitochondria in hepatic stellate cells. , 2021, Hepatobiliary & pancreatic diseases international : HBPD INT.

[7]  Elias Adikwu,et al.  Valporic acid-induced hepatotoxicity in rats: Protective effect of selenium , 2021 .

[8]  H. Parlakpınar,et al.  Protective effects of naringin on valproic acid-induced hepatotoxicity in rats. , 2021, Tissue & cell.

[9]  J. Uetrecht,et al.  Idiosyncratic Drug-Induced Liver Injury: Mechanistic and Clinical Challenges , 2021, International journal of molecular sciences.

[10]  A. Borobia,et al.  Valproic Acid-Induced Liver Injury: A Case-Control Study from a Prospective Pharmacovigilance Program in a Tertiary Hospital , 2021, Journal of clinical medicine.

[11]  R. Teschke,et al.  Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues , 2020, Annals of translational medicine.

[12]  D. Gharib,et al.  Antioxidant and anti-inflammatory properties of alpha lipoic acid protect against valproic acid induced liver injury. , 2020, Canadian journal of physiology and pharmacology.

[13]  Guangchun Sun,et al.  Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma , 2020, Fundamental & clinical pharmacology.

[14]  Yingjie Guo,et al.  Involvement of CYP2E1-ROS-CD36/DGAT2 axis in the pathogenesis of VPA-induced hepatic steatosis in vivo and in vitro. , 2020, Toxicology.

[15]  T. Yokoi,et al.  Models of Idiosyncratic Drug-Induced Liver Injury. , 2020, Annual review of pharmacology and toxicology.

[16]  M. Hüttemann,et al.  Valproate inhibits mitochondrial bioenergetics and increases glycolysis in Saccharomyces cerevisiae , 2020, Scientific Reports.

[17]  J. Kleinjans,et al.  Valproic acid promotes mitochondrial dysfunction in primary human hepatocytes in vitro; impact of C/EBPα-controlled gene expression , 2020, Archives of Toxicology.

[18]  Hongliang Li,et al.  Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. , 2020, Free radical biology & medicine.

[19]  Po-Chen Lin,et al.  Valproic Acid-Induced Hyperammonemic Encephalopathy in a Patient with Bipolar Disorder: A Case Report , 2020, Brain sciences.

[20]  Sophia L. Samodelov,et al.  Obeticholic Acid Ameliorates Valproic Acid–Induced Hepatic Steatosis and Oxidative Stress , 2020, Molecular Pharmacology.

[21]  Amany M Gad,et al.  Ellagic acid attenuates liver toxicity induced by valproic acid in rats. , 2020, Journal of pharmacological sciences.

[22]  R. Citraro,et al.  Butyrate prevents valproate‐induced liver injury: In vitro and in vivo evidence , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  Jie Sun,et al.  Valproic acid targets HDAC1/2 and HDAC1/PTEN/Akt signalling to inhibit cell proliferation via the induction of autophagy in gastric cancer , 2020, The FEBS journal.

[24]  C. Shan,et al.  Metabolomics reveals the effect of valproic acid on MCF-7 and MDA-MB-231 cells , 2020, Xenobiotica; the fate of foreign compounds in biological systems.

[25]  D. Larrey,et al.  Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation , 2019, Front. Pharmacol..

[26]  Xiang-chang Zeng,et al.  Ginsenoside compound K alleviates sodium valproate-induced hepatotoxicity in rats via antioxidant effect, regulation of peroxisome pathway and iron homeostasis. , 2019, Toxicology and applied pharmacology.

[27]  M. Uzun,et al.  Melatonin ameliorates sodium valproate-induced hepatotoxicity in rats , 2019, Molecular Biology Reports.

[28]  Limei Zhao,et al.  Lipidomic Profiling Reveals Disruption of Lipid Metabolism in Valproic Acid-Induced Hepatotoxicity , 2019, Front. Pharmacol..

[29]  E. Björnsson,et al.  Drug-Induced Liver Injury - Types and Phenotypes. , 2019, The New England journal of medicine.

[30]  Rongsheng Tong,et al.  RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review) , 2019, International journal of molecular medicine.

[31]  J. Lykkesfeldt,et al.  A role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease , 2019, Basic & clinical pharmacology & toxicology.

[32]  D. Scolnik,et al.  Levocarnitine for the Treatment of Valproic Acid–Induced Hyperammonemic Encephalopathy in Children: The Experience of a Large, Tertiary Care Pediatric Hospital and a Poison Center , 2017, American journal of therapeutics.

[33]  Xiao-peng Lu,et al.  Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update. , 2019, Current pharmaceutical design.

[34]  J. Park,et al.  Hepatic lipid homeostasis by peroxisome proliferator-activated receptor gamma 2☆ , 2018, Liver research.

[35]  R. Teschke.  Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method , 2018, Expert opinion on drug metabolism & toxicology.

[36]  N. Ahmed,et al.  Agmatine protects against sodium valproate–induced hepatic injury in mice via modulation of nuclear factor‐κB/inducible nitric oxide synthetase pathway , 2018, Journal of biochemical and molecular toxicology.

[37]  Vijay Gayam,et al.  Valproic acid induced acute liver injury resulting in hepatic encephalopathy- a case report and literature review , 2018, Journal of community hospital internal medicine perspectives.

[38]  J. Kleinjans,et al.  Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. , 2018, Toxicology letters.

[39]  E. Zoidis,et al.  Selenium-Dependent Antioxidant Enzymes: Actions and Properties of Selenoproteins , 2018, Antioxidants.

[40]  Janthima Methaneethorn.  A systematic review of population pharmacokinetics of valproic acid , 2018, British journal of clinical pharmacology.

[41]  Kosuke Saito,et al.  Ether-phosphatidylcholine characterized by consolidated plasma and liver lipidomics is a predictive biomarker for valproic acid-induced hepatic steatosis. , 2018, The Journal of toxicological sciences.

[42]  Xiaowei Wang,et al.  Valproic acid sensitizes breast cancer cells to hydroxyurea through inhibiting RPA2 hyperphosphorylation-mediated DNA repair pathway. , 2017, DNA repair.

[43]  J. Kleinjans,et al.  Nuclear and Mitochondrial DNA Methylation Patterns Induced by Valproic Acid in Human Hepatocytes , 2017, Chemical research in toxicology.

[44]  R. Heidari,et al.  Valproic Acid-Induced Hepatotoxicity and the Protective Role of Thiol Reductants , 2017 .

[45]  E. Zamani,et al.  Zinc Deficiency and Oxidative Stress Involved in Valproic Acid Induced Hepatotoxicity: Protection by Zinc and Selenium Supplementation , 2017, Biological Trace Element Research.

[46]  Shufeng Zhou,et al.  Computational Identification of the Paralogs and Orthologs of Human Cytochrome P450 Superfamily and the Implication in Drug Discovery , 2016, International journal of molecular sciences.

[47]  C. Anuradha,et al.  High-calorie diet inflates steatogenic effects of valproic acid in mice , 2016, Toxicology mechanisms and methods.

[48]  B. Stefanovic,et al.  Valproic acid suppresses collagen by selective regulation of Smads in conjunctival fibrosis , 2015, Journal of Molecular Medicine.

[49]  H. Nishiura,et al.  Sodium valproate, a histone deacetylase inhibitor, modulates the vascular endothelial growth inhibitor-mediated cell death in human osteosarcoma and vascular endothelial cells. , 2015, International journal of oncology.

[50]  G. Jena,et al.  Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat. , 2015, Experimental and molecular pathology.

[51]  A. Elmarakby,et al.  Valproate-Induced Liver Injury: Modulation by the Omega-3 Fatty Acid DHA Proposes a Novel Anticonvulsant Regimen , 2014, Drugs in R&D.

[52]  P. Pockros,et al.  Drug-induced liver injury from antiepileptic drugs. , 2013, Clinics in liver disease.

[53]  M. Neuman,et al.  Adverse drug reactions induced by valproic acid. , 2013, Clinical biochemistry.

[54]  M. Hosseini,et al.  Toxicity of valproic acid in isolated rat liver mitochondria , 2013, Toxicology mechanisms and methods.

[55]  R. Altman,et al.  Valproic acid pathway: pharmacokinetics and pharmacodynamics , 2013, Pharmacogenetics and genomics.

[56]  M. Arafa,et al.  Influence of Silymarin on Valproic Acid Induced Hepatotoxicity in Adult Male Albino Rats , 2013 .

[57]  R. Yanardag,et al.  Effects of vitamin U (S-methyl methionine sulphonium chloride) on valproic acid induced liver injury in rats. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[58]  J. Pourahmad,et al.  A new approach on valproic acid induced hepatotoxicity: involvement of lysosomal membrane leakiness and cellular proteolysis. , 2012, Toxicology in vitro : an international journal published in association with BIBRA.

[59]  A. El-Mowafy,et al.  Eicosapentaenoic acid ablates valproate-induced liver oxidative stress and cellular derangement without altering its clearance rate: dynamic synergy and therapeutic utility. , 2011, Biochimica et biophysica acta.

[60]  Tony K. L. Kiang,et al.  Glutathione depletion by valproic acid in sandwich-cultured rat hepatocytes: Role of biotransformation and temporal relationship with onset of toxicity. , 2011, Toxicology and applied pharmacology.

[61]  B. Fromenty,et al.  Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. , 2011, Journal of hepatology.

[62]  William M. Lee,et al.  Drug‐induced acute liver failure: Results of a U.S. multicenter, prospective study , 2010, Hepatology.

[63]  R. Naviaux,et al.  POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders , 2010, Seizure.

[64]  J. -. Park,et al.  TNF-α-induced ROS production triggering apoptosis is directly linked to Romo1 and Bcl-XL , 2010, Cell Death and Differentiation.

[65]  I. T. de Almeida,et al.  Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. , 2010, Biochemical pharmacology.

[66]  E. Trinka,et al.  Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment , 2009, Epilepsy Research.

[67]  I. Harting,et al.  Status epilepticus in children with Alpers’ disease caused by POLG1 mutations: EEG and MRI features , 2009, Epilepsia.

[68]  K. Meador,et al.  Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. , 2009, The New England journal of medicine.

[69]  F. Chiarelli,et al.  Nonalcoholic fatty liver disease during valproate therapy , 2009, European Journal of Pediatrics.

[70]  R. Remmel,et al.  Effect of Aging on Glucuronidation of Valproic Acid in Human Liver Microsomes and the Role of UDP-Glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10 , 2009, Drug Metabolism and Disposition.

[71]  M. Zeviani,et al.  155th ENMC workshop: Polymerase gamma and disorders of mitochondrial DNA synthesis, 21–23 September 2007, Naarden, The Netherlands , 2008, Neuromuscular Disorders.

[72]  You-Sun Kim,et al.  TNFα and reactive oxygen species in necrotic cell death , 2008, Cell Research.

[73]  A. Bergquist,et al.  Acute liver failure in Sweden: etiology and outcome , 2007, Journal of internal medicine.

[74]  N. Chalasani,et al.  Etiology of New-Onset Jaundice: How Often Is It Caused by Idiosyncratic Drug-Induced Liver Injury in The United States? , 2007, The American Journal of Gastroenterology.

[75]  Xin Zhou,et al.  Levels of selenium, zinc, copper, and antioxidant enzyme activity in patients with leukemia , 2007, Biological Trace Element Research.

[76]  C. Eapen,et al.  Oxidative stress in experimental liver microvesicular steatosis: Role of mitochondria and peroxisomes , 2006, Journal of gastroenterology and hepatology.

[77]  David A. Brenner,et al.  Mechanisms of Liver Injury. I. TNF-α-induced liver injury: role of IKK, JNK, and ROS pathways , 2006 .

[78]  G. Karikas,et al.  Valproic acid monotherapy induces DNA oxidative damage. , 2006, Toxicology.

[79]  Thomas K. H. Chang,et al.  Oxidative Stress as a Mechanism of Valproic Acid-Associated Hepatotoxicity , 2006, Drug metabolism reviews.

[80]  Thomas K. H. Chang,et al.  Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[81]  Thomas K. H. Chang,et al.  Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[82]  D. Wysowski,et al.  Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. , 2005, Archives of internal medicine.

[83]  Thomas K. H. Chang,et al.  Valproic acid glucuronidation is associated with increases in 15-F2t-isoprostane in rats. , 2005, Free radical biology & medicine.

[84]  D. Wyszynski,et al.  Teratogenicity of sodium valproate , 2005, Expert opinion on drug safety.

[85]  E. Trinka,et al.  Valproate therapy and nonalcoholic fatty liver disease , 2004, Annals of neurology.

[86]  S. Johannessen,et al.  Valproate: past, present, and future. , 2006, CNS drug reviews.

[87]  Thomas K. H. Chang,et al.  The effect of valproic acid on hepatic and plasma levels of 15-F2t-isoprostane in rats. , 2003, Free radical biology & medicine.

[88]  H. Wong,et al.  Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[89]  M. Uysal,et al.  Effect of acute and chronic administration of sodium valproate on lipid peroxidation and antioxidant system in rat liver. , 1999, Pharmacology & toxicology.

[90]  M. Nagao,et al.  Influence of valproic acid on the expression of various acyl‐CoA dehydrogenases in rats , 1999, Pediatrics international : official journal of the Japan Pediatric Society.

[91]  H. Nau,et al.  Valproate (VPA) Metabolites in Various Clinical Conditions of Probable VPA‐Associated Hepatotoxicity , 1993, Epilepsia.

[92]  S. Evans,et al.  Early changes in hepatic redox homeostasis following treatment with a single dose of valproic acid. , 1990, Biochemical pharmacology.

[93]  P. Friel.  Valproyl CoA: an active metabolite of valproate? , 1990, Medical hypotheses.

[94]  G. Zaccara,et al.  Clinical Pharmacokinetics of Valproic Acid — 1988 , 1988, Clinical pharmacokinetics.

[95]  W. Maenhaut,et al.  Selenium, zinc, and copper changes with valproic acid , 1984, Neurology.

[96]  G. Carraz,et al.  [Pharmacodynamic properties of N-dipropylacetic acid]. , 1963, Therapie.